B. Benettaib

发表

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

A. Ganser, G. Mufti, B. Quesnel, 2014, European journal of haematology.

Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

K. Norga, D. Faller, G. Vassal, 2020, European journal of cancer.

ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children.

W. Klapper, K. Norga, B. Burkhardt, 2019, European journal of cancer.

ACCELERATE and EMA Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children Authors

W. Klapper, K. Norga, B. Burkhardt, 2019 .

Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.

S. Rives, A. Baruchel, I. Baumann, 2021, Blood advances.

Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study

A. Ganser, G. Mufti, B. Quesnel, 2013 .

Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

J. Fangusaro, D. Hargrave, M. Massimino, 2021, Frontiers in Oncology.

Results of a phase 2, multicenter, single‐arm, open‐label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia

T. Alonzo, P. Brown, J. Levine, 2021, Pediatric blood & cancer.

Upfront azacitidine (AZA) in juvenile myelomonocytic leukemia (JMML): Interim analysis of the prospective AZA-JMML-001 study.

S. Rives, A. Baruchel, I. Baumann, 2019, Journal of Clinical Oncology.

Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols

Martha Donoghue, G. Vassal, G. Reaman, 2019, Therapeutic innovation & regulatory science.

Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

K. Norga, D. Faller, G. Vassal, 2020, European journal of cancer.